Medico Remedies Limited (NSE:MEDICO)
India
· Delayed Price · Currency is INR 56.25
-1.88 (-3.23%)
Mar 13, 2025, 3:29 PM IST
Medico Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 1,510 | 1,449 | 1,404 | 1,210 | 1,224 | 886.36 | Upgrade
|
| Other Revenue | - | - | - | 0 | - | - | Upgrade
|
| Revenue | 1,510 | 1,449 | 1,404 | 1,210 | 1,224 | 886.36 | Upgrade
|
| Revenue Growth (YoY) | 14.72% | 3.19% | 16.04% | -1.12% | 38.08% | -9.27% | Upgrade
|
| Cost of Revenue | 1,127 | 1,112 | 1,057 | 887.41 | 934.6 | 683.51 | Upgrade
|
| Gross Profit | 382.7 | 336.79 | 347.51 | 322.8 | 289.3 | 202.85 | Upgrade
|
| Selling, General & Admin | 61.06 | 59.68 | 57.91 | 60.09 | 48.9 | 39.42 | Upgrade
|
| Other Operating Expenses | 191.81 | 148.02 | 193.41 | 188.98 | 188 | 134.92 | Upgrade
|
| Operating Expenses | 282.89 | 236.49 | 278.52 | 271.25 | 253.4 | 190.98 | Upgrade
|
| Operating Income | 99.81 | 100.3 | 68.99 | 51.55 | 35.9 | 11.87 | Upgrade
|
| Interest Expense | -7.31 | -6.43 | -5.8 | -5.07 | -7.9 | -8.34 | Upgrade
|
| Interest & Investment Income | 0.94 | 0.94 | 1.01 | 0.7 | 4.2 | 3.9 | Upgrade
|
| Currency Exchange Gain (Loss) | 20.31 | 20.31 | 38.46 | 19.59 | 6.1 | 16.95 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.71 | -1.81 | -1.67 | -1.56 | -1.3 | -2.25 | Upgrade
|
| EBT Excluding Unusual Items | 120.47 | 113.32 | 100.99 | 65.22 | 37 | 22.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.03 | 0.03 | - | -0.39 | - | 0.02 | Upgrade
|
| Pretax Income | 120.5 | 113.35 | 100.99 | 64.83 | 37 | 22.15 | Upgrade
|
| Income Tax Expense | 31.99 | 30.44 | 28.57 | 16.71 | 11.1 | 5.85 | Upgrade
|
| Net Income | 88.52 | 82.91 | 72.42 | 48.12 | 25.9 | 16.3 | Upgrade
|
| Net Income to Common | 88.52 | 82.91 | 72.42 | 48.12 | 25.9 | 16.3 | Upgrade
|
| Net Income Growth | 27.22% | 14.49% | 50.49% | 85.79% | 58.86% | 3.84% | Upgrade
|
| Shares Outstanding (Basic) | 84 | 83 | 83 | 83 | 83 | 83 | Upgrade
|
| Shares Outstanding (Diluted) | 84 | 83 | 83 | 83 | 83 | 83 | Upgrade
|
| Shares Change (YoY) | 1.38% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 1.06 | 1.00 | 0.87 | 0.58 | 0.31 | 0.20 | Upgrade
|
| EPS (Diluted) | 1.06 | 1.00 | 0.87 | 0.58 | 0.31 | 0.20 | Upgrade
|
| EPS Growth | 25.49% | 14.84% | 50.03% | 85.79% | 58.86% | 3.95% | Upgrade
|
| Free Cash Flow | - | 2.04 | 15.75 | -0.51 | -282.7 | -23.61 | Upgrade
|
| Free Cash Flow Per Share | - | 0.02 | 0.19 | -0.01 | -3.41 | -0.28 | Upgrade
|
| Gross Margin | 25.35% | 23.24% | 24.74% | 26.67% | 23.64% | 22.89% | Upgrade
|
| Operating Margin | 6.61% | 6.92% | 4.91% | 4.26% | 2.93% | 1.34% | Upgrade
|
| Profit Margin | 5.86% | 5.72% | 5.16% | 3.98% | 2.12% | 1.84% | Upgrade
|
| Free Cash Flow Margin | - | 0.14% | 1.12% | -0.04% | -23.10% | -2.66% | Upgrade
|
| EBITDA | 125.64 | 124.94 | 92.05 | 72.35 | 52.4 | 28.5 | Upgrade
|
| EBITDA Margin | 8.32% | 8.62% | 6.55% | 5.98% | 4.28% | 3.22% | Upgrade
|
| D&A For EBITDA | 25.83 | 24.64 | 23.05 | 20.8 | 16.5 | 16.64 | Upgrade
|
| EBIT | 99.81 | 100.3 | 68.99 | 51.55 | 35.9 | 11.87 | Upgrade
|
| EBIT Margin | 6.61% | 6.92% | 4.91% | 4.26% | 2.93% | 1.34% | Upgrade
|
| Effective Tax Rate | 26.54% | 26.86% | 28.29% | 25.78% | 30.00% | 26.40% | Upgrade
|
| Revenue as Reported | 1,539 | 1,470 | 1,444 | 1,231 | 1,234 | 907.33 | Upgrade
|
| Advertising Expenses | - | 0.47 | 0.37 | 5.66 | 3.9 | 1.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.